A61P 9/10
Drugs for disorders of the cardiovascular system: for treating ischaemic or atherosclerotic
Official title: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P9/10 (Drugs for disorders of the cardiovascular system: for treating ischaemic or atherosclerotic) appears on 30,878 US grants and 43,761 published applications in this corpus.
Search patents in A61P- Granted patents
- 30,878
- Published applications
- 43,761
- Assignees
- 9,218
- Inventors
- 60,939
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 13 | 0 |
| 1977 | 9 | 0 |
| 1978 | 19 | 0 |
| 1979 | 17 | 0 |
| 1980 | 26 | 0 |
| 1981 | 42 | 0 |
| 1982 | 33 | 0 |
| 1983 | 36 | 0 |
| 1984 | 54 | 0 |
| 1985 | 60 | 0 |
| 1986 | 69 | 0 |
| 1987 | 78 | 0 |
| 1988 | 91 | 0 |
| 1989 | 104 | 0 |
| 1990 | 109 | 0 |
| 1991 | 127 | 0 |
| 1992 | 157 | 0 |
| 1993 | 130 | 0 |
| 1994 | 150 | 0 |
| 1995 | 234 | 0 |
| 1996 | 240 | 0 |
| 1997 | 353 | 0 |
| 1998 | 447 | 0 |
| 1999 | 428 | 0 |
| 2000 | 467 | 0 |
| 2001 | 584 | 186 |
| 2002 | 763 | 1044 |
| 2003 | 836 | 1746 |
| 2004 | 677 | 2254 |
| 2005 | 712 | 2196 |
| 2006 | 898 | 2162 |
| 2007 | 946 | 2316 |
| 2008 | 1024 | 2576 |
| 2009 | 1216 | 2926 |
| 2010 | 1686 | 3441 |
| 2011 | 1698 | 2917 |
| 2012 | 1929 | 2632 |
| 2013 | 2059 | 2121 |
| 2014 | 1997 | 2152 |
| 2015 | 1723 | 1890 |
| 2016 | 1413 | 1824 |
| 2017 | 1402 | 1572 |
| 2018 | 1188 | 1411 |
| 2019 | 1070 | 1337 |
| 2020 | 895 | 1094 |
| 2021 | 744 | 953 |
| 2022 | 555 | 790 |
| 2023 | 423 | 677 |
| 2024 | 380 | 632 |
| 2025 | 373 | 567 |
| 2026 | 194 | 345 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- PHD inhibitor compounds, compositions, and use6 Oct 2026US 12,753,161 B2Akebia Therapeutics, Inc.
- Pharmaceutical composition for treatment or prevention of ischemic cardiovascular disease29 Sep 2026US 12,746,220 B2Industry-Academic Cooperation Foundation, Yonsei University
- Use of composition containing cilostazol in cerebrovascular diseases29 Sep 2026US 12,746,234 B2Neurodawn Pharmaceutical Co., Ltd.
- Cyclic peptide compounds and methods of use29 Sep 2026US 12,746,269 B2
- Treatment or prevention of ischaemic stroke reperfusion injury22 Sep 2026US 12,740,955 B2Cambridge Enterprise Limited
- Tomm6-interacting extracts and compounds for use in the treatment and prophylaxis of nervous system diseases, atherosclerosis, hepatitis b infection and human papilloma virus (hpv) infection8 Oct 2026US 2026/0306473 A1
- Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation8 Oct 2026US 2026/0306492 A1Bristol-Myers Squibb Company
- Amorphous calcium carbonate for prevention and treatment of myocardial ischemia8 Oct 2026US 2026/0306533 A1Amorphical Ltd.
- Intranasal delivery of cd34+ cells for the treatment of stroke8 Oct 2026US 2026/0306537 A1Cellprothera
- Metabolic target for therapy of chronic vascular inflammation8 Oct 2026US 2026/0308588 A1Yale University
Most cited
By later US patents
- Modular infusion device and method1,554US 6,749,587 B2Insulet Corporation · 2004
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005